0000899243-20-015872.txt : 20200609 0000899243-20-015872.hdr.sgml : 20200609 20200609210021 ACCESSION NUMBER: 0000899243-20-015872 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200605 FILED AS OF DATE: 20200609 DATE AS OF CHANGE: 20200609 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Coulie Bernard CENTRAL INDEX KEY: 0001808895 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39303 FILM NUMBER: 20953327 MAIL ADDRESS: STREET 1: C/O PLIANT THERAPEUTICS, INC. STREET 2: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PLIANT THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001746473 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474272481 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-481-6770 MAIL ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-05 0 0001746473 PLIANT THERAPEUTICS, INC. PLRX 0001808895 Coulie Bernard C/O PLIANT THERAPEUTICS, INC. 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Common Stock 2020-04-30 4 M 0 613 6.22 A 613 D Common Stock 2020-04-30 4 M 0 48227 2.08 A 48840 D Common Stock 2020-06-05 4 C 0 25397 A 474317 I See footnote Stock Option (right to buy) 6.22 2020-03-31 4 A 0 377336 0.00 A 2030-03-30 Common Stock 377336 377336 D Stock Option (right to buy) 6.22 2020-04-30 4 M 0 613 0.00 D 2030-03-30 Common Stock 613 376723 D Stock Option (right to buy) 2.08 2020-04-30 4 M 0 48227 0.00 D 2029-01-23 Common Stock 48227 343380 D Series B Preferred Stock 2020-06-05 4 C 0 181594 0.00 D Common Stock 25397 0 I See footnote On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. The Series B Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date. 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date. /s/ Anthony Franks, attorney-in-fact 2020-06-09